Quick Recap
GI & Hepatology System, Protocol 5/13. Distinct from Acute Liver Failure (prior protocol, occurs WITHOUT pre-existing cirrhosis) — ACLF occurs ON TOP OF chronic liver disease/cirrhosis.
1. Definition
ACLF = acute deterioration of liver function in patients WITH cirrhosis, resulting in failure of one or more EXTRAHEPATIC organs. Distinct from both acute liver failure (no underlying chronic disease) and simple decompensated cirrhosis (hepatic decompensation without the extrahepatic organ failure component).
Precipitants: alcohol consumption, infection, hepatitis B reactivation. No precipitant is identified in up to 45% of cases — a substantial proportion remains cryptogenic despite workup.
Mortality scales steeply with organ failure count: in the setting of 3 or more organ failures, 28-day transplant-free mortality is 78% — organ failure count is the dominant prognostic driver, more so than any single lab value.
2. Underlying Framework — Decompensated Cirrhosis Background
ACLF sits on a spectrum with decompensated cirrhosis, whose major complications are: ascites, GI bleeding, hepatic encephalopathy, and AKI — all driven by the shared pathophysiologic axis of portal hypertension + hepatic synthetic dysfunction. Understanding ACLF requires recognizing it as an ACUTE, ORGAN-FAILURE-DEFINED escalation on top of this chronic baseline, not a separate disease process.
3. Ascites (Most Frequent Decompensation Manifestation)
Median 2-year mortality with ascites: 50% — ascites onset itself is a major prognostic inflection point in cirrhosis, not just a symptom to manage.
Diagnosis: cirrhotic (portal-hypertensive) ascites identified by serum-to-ascites albumin gradient (SAAG) >1.1 g/dL.
Diagnostic paracentesis required for: ALL new-onset ascites, or any change in clinical condition (confusion, AKI, GI bleeding) in a patient with known ascites — do not assume a known cause for a new decompensation event without re-tapping.
Paracentesis is SAFE even with coagulopathy and thrombocytopenia — do not withhold this essential diagnostic/therapeutic procedure for lab-based coagulopathy alone (mirrors the general critical care principle against reflexive pre-procedure correction). Preferred sites: right and left lower abdominal quadrants; complications are rare, mostly abdominal wall hematoma. Send ascites for albumin, cell count with differential, and inoculate directly into blood culture media (bedside inoculation improves culture yield vs sending fluid to the lab for later inoculation).
Management: oral furosemide + spironolactone is standard, but diuretics may need to be WITHHELD in ICU patients with AKI, hypovolemia, or electrolyte disturbance — a common and important ICU-specific deviation from standard outpatient ascites management.
4. Hepatorenal Syndrome-AKI (HRS-AKI) — A Distinct AKI Phenotype
Consensus AKI-in-cirrhosis definition: sCr rise >=0.3 mg/dL within 48h, OR sCr rise >=1.5x baseline.
HRS-AKI specifically requires: kidney injury + cirrhosis with ascites + ABSENCE of competing diagnoses (parenchymal kidney disease, shock, nephrotoxic medication exposure) + NO response to diuretic withdrawal and albumin challenge (25% albumin 1 g/kg IBW/day for 48h).
HRS-AKI staging:
Stage | Criteria |
1a | sCr <1.5 mg/dL with rise >0.3 mg/dL or 1.5-2x baseline |
1b | sCr >=1.5 mg/dL with rise >0.3 mg/dL or 1.5-2x baseline |
2 | sCr rise >2-3x baseline |
3 | sCr rise >3x baseline, OR sCr >=4.0 mg/dL with acute rise >=0.3, OR RRT initiation |
Management sequence:
- Discontinue diuretics
- Volume expansion with IV 25% albumin (the standard albumin challenge, also part of the diagnostic criteria above)
- If no response to albumin: terlipressin (vasopressin receptor agonist) — US approved starting dose 0.85mg IV over 2 minutes q6h, for 3 days, then reassess based on creatinine response
- Terlipressin contraindications/cautions: NOT recommended if baseline sCr >5 mg/dL; CONTRAINDICATED if SpO2 <90% or coronary/peripheral/mesenteric ischemia present; volume overload or ACLF grade >=3 patients are at INCREASED RESPIRATORY FAILURE RISK with terlipressin — monitor closely or avoid treatment in these specific high-risk subgroups
- Earlier intervention for HRS-AKI correlates with greater likelihood of improvement — do not delay the albumin challenge and terlipressin escalation once HRS-AKI is suspected
5. Immediate Stabilization (ABCDE) — General ACLF Framework
Airway/Breathing: standard indications; watch for aspiration risk with encephalopathy (see Hepatic Encephalopathy protocol).
Circulation: identify and treat the precipitant aggressively (infection workup/treatment, alcohol withdrawal management, hepatitis B antiviral if reactivation identified); manage HRS-AKI per Section 4 if renal failure present; treat variceal bleeding per UGIB protocol if present, applying the same PRBC-privileged, non-aggressive-component-transfusion principles.
Disability: assess/grade hepatic encephalopathy (West Haven criteria, see Hepatic Encephalopathy protocol) as part of organ failure assessment.
Checklist:
6. Malnutrition and Nutrition
~2/3 of end-stage liver disease patients awaiting transplant are malnourished — a major, underappreciated comorbidity in this population.
ICU patients are frequently made NPO for GI bleeding, high vasopressor requirements, procedure planning, or encephalopathy — actively identify and address barriers to nutrition rather than defaulting to prolonged NPO status.
Enteral nutrition should start within 24-48 hours of ICU admission if oral intake is insufficient.
Higher protein goals generally recommended: 1.2-2 g/kg/day based on IDEAL body weight — protein should NOT be restricted (same principle established in the Acute Liver Failure protocol, applies equally here despite older, now-outdated teaching about protein restriction in liver disease/encephalopathy).
Parenteral nutrition can be considered for hospitalized patients meeting frailty/sarcopenia criteria — preferable to no supplementation, but a SECOND-LINE option behind enteral nutrition.
7. Organ Support
Albumin + terlipressin for HRS-AKI; CRRT if renal replacement needed (preferred over intermittent HD for hemodynamic tolerance, same principle as Acute Liver Failure protocol); mechanical ventilation with attention to terlipressin-associated respiratory risk if used; early enteral nutrition with adequate protein targets; standard ICU supportive care for each failing organ system.
8. Consultation Matrix
Consultation | Trigger | Timing |
Hepatology/Liver Transplant | All ACLF, especially with multi-organ failure | Immediate |
Nephrology | HRS-AKI, RRT consideration | Immediate if renal failure |
Infectious Disease | Suspected infectious precipitant | Immediate |
Nutrition/Dietitian | Malnutrition assessment, enteral nutrition planning | Early, within 24-48h |
9. Monitoring Framework
Serial organ failure assessment (count and trend, given its prognostic dominance), serial creatinine for HRS-AKI staging/terlipressin response, respiratory monitoring if terlipressin used (esp. ACLF grade >=3/volume overloaded), serial encephalopathy grading, nutritional status tracking.
10. Complications
Multi-organ failure progression, HRS-AKI progression to RRT-dependence, terlipressin-associated respiratory failure (in high-risk subgroups), variceal hemorrhage, infection (spontaneous bacterial peritonitis — see dedicated considerations in related protocols), malnutrition-related complications (sarcopenia, immune dysfunction). Prevention: early precipitant identification/treatment, early albumin/terlipressin escalation for HRS-AKI, careful terlipressin patient selection, early nutrition. Rescue: CRRT for renal failure, liver transplant evaluation for eligible candidates.
11. Escalation & De-escalation
Escalate: increasing organ failure count -> reassess transplant urgency/eligibility, escalate organ-specific support (CRRT, ventilation, vasopressors); HRS-AKI not responding to albumin -> terlipressin per Section 4 protocol.
De-escalate: precipitant treated, organ failures resolving, creatinine improving on terlipressin -> continue/complete the 3-day terlipressin course then reassess, wean organ support, transition toward standard decompensated cirrhosis management.
12. ICU Discharge Criteria
Organ failure count stable/decreasing, precipitant identified and treated (or excluded after appropriate workup), HRS-AKI responding or stabilized, nutrition established, transplant evaluation status clarified, ascites/encephalopathy at a manageable baseline.
13. Documentation & Medicolegal Checklist
14. Key Guidelines
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 AASLD practice guidance. Hepatology. 2021;74(2):1014-1048 — primary reference for ascites/HRS-AKI management.
15. Controversies
The ~45% of ACLF cases with no identifiable precipitant represent a genuine diagnostic and prognostic gap — management in this subgroup is necessarily more supportive/empiric. Terlipressin dosing and duration protocols continue to be refined, and its respiratory risk profile in specific subgroups (volume overload, ACLF grade >=3) requires ongoing careful patient selection rather than blanket application. Optimal protein target (1.2-2 g/kg/day range) lacks precise ICU-cirrhosis-specific dosing data, leaving meaningful practice variation.
16. References
- Al-Obaid L, Korenblat KM. End-Stage Liver Disease. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 51).
- Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, SBP, and HRS: 2021 AASLD practice guidance. Hepatology. 2021;74(2):1014-1048.
- Boike JR, Thornburg BG, Asrani SK, et al. North American practice-based recommendations for TIPS in portal hypertension. Clin Gastroenterol Hepatol. 2022;20(8):1636-1662.
- Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437 (CANONIC study — foundational ACLF definition/characterization, referenced framework).
See also: Acute Liver Failure (distinct entity, no underlying cirrhosis), Hepatic Encephalopathy, and Upper GI Bleed (GI & Hepatology System) for closely related decompensation complications.